Trial Profile
A Multicenter, Randomized, Open-Label Phase Ⅲ Trial to Compare Efficacy and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Goserelin
- Indications Carcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Luye Pharma Group
- 20 May 2023 Results assessing the efficacy and safety of LY01005 in Chinese patients with prostate cancer, published in the Chinese Medical Journal.
- 06 Sep 2021 Primary endpoint (The cumulative percentage of subjects with the maintenance of serum testosterone 50 ng/dL (1.735 nmol/L) from Day 29 to Day 85.) has been met according to Luye Pharma media release.
- 06 Sep 2021 Primary endpoint (The percentage of subjects with serum testosterone 50 ng/dL (1.735 nmol/L) on Day 29 after the first dose.) has been met according to Luye Pharma media release.